Figure 3.

Landmark analyses of PFS and EFS according to CCyR at 6 months. A total of 199 patients (103 patients in arm A and 96 patients in arm B who were still on study treatment and could, therefore, be analyzed by conventional cytogenetics at month 6 after treatment initiation were categorized according to CCyR. The following end-points were analyzed: progression into accelerated phase and blast crisis (A) and EFS (B). Events were defined as follows: death from any cause during treatment, progression to accelerated phase and blast crisis, loss of a complete hematologic response, loss of a MCyR.